The Ophthalmic Drugs Market was valued at USD 38.20 billion in 2024, and is projected to reach USD 62.08 billion by 2030, rising at a CAGR of 8.50%. The rising awareness about ophthalmic disorders and the surge in demand for ophthalmic drugs are the factors propelling the market growth. Moreover, an increase in the prevalence of eye diseases such as age-related macular degeneration, cataract, dry eye, diabetic retinopathy, glaucoma, and others are anticipated to boost the demand for ophthalmic drugs. ![Ophthalmic Drugs Market]( "Ophthalmic Drugs Market")
According to BrightFocus Foundation in 2021, it is estimated that over 3 million Americans are living with glaucoma, and, among them over 2.7 million patients were affected by the most common type of glaucoma i.e. open-angle glaucoma. Moreover, 3.3 million people are affected by blindness and low vision in the U.S. Some of the major risk factors for glaucoma and blindness are, higher age, family history, thin cornea, and high eye pressure. This creates a wide population base for ophthalmic drugs, thereby, ensuring lucrative growth.
Furthermore, ocular therapeutic and drug delivery companies are receiving funding to expedite R&D for advancements in technologies to develop novel drugs, which is likely to fuel market growth. For instance, in June 2020, Re-Vana Therapeutics received USD 3.25 million in pre-series A funding from Qubis, ExSight Ventures, LLC, Clarendon Fund Managers, Visionary Ventures, and Techstart Ventures LLP. The funding is expected to boost the development of Re-Vana Therapeutics’ EyeLief & OcuLief biodegradable technologies that can be used for a small molecule as well as biologics delivery.
Moreover, the rising geriatric population is the key driver for the ophthalmic drugs market growth. According to Safe Eyes America, the most common risk factors for ophthalmic diseases are high age, family history, diabetes, and high blood pressure. For instance, as per AMERICA’s HEALTH RANKINGS senior report 2021 it was estimated that more than 54 million adults of age more than 65 live in the U.S., and that population accounted for 16.5% of the total population. According to Macular Degeneration Research AMD is the leading reason for blindness in U.S. people over the age of 60.
Ongoing regulatory approvals for ophthalmic products are likely to support market growth. For instance, in June 2022 Santen Pharmaceutical Co., Ltd announced that it has got marketing and manufacturing approval for the dry eye disease treatment DIQUAS LX ophthalmic solution in Japan. This solution is the improved formulation that has reduced dosing frequency and improved patient compliance.
According to BrightFocus Foundation in 2021, it is estimated that over 3 million Americans are living with glaucoma, and, among them over 2.7 million patients were affected by the most common type of glaucoma i.e. open-angle glaucoma. Moreover, 3.3 million people are affected by blindness and low vision in the U.S. Some of the major risk factors for glaucoma and blindness are, higher age, family history, thin cornea, and high eye pressure. This creates a wide population base for ophthalmic drugs, thereby, ensuring lucrative growth.
Furthermore, ocular therapeutic and drug delivery companies are receiving funding to expedite R&D for advancements in technologies to develop novel drugs, which is likely to fuel market growth. For instance, in June 2020, Re-Vana Therapeutics received USD 3.25 million in pre-series A funding from Qubis, ExSight Ventures, LLC, Clarendon Fund Managers, Visionary Ventures, and Techstart Ventures LLP. The funding is expected to boost the development of Re-Vana Therapeutics’ EyeLief & OcuLief biodegradable technologies that can be used for a small molecule as well as biologics delivery.
Moreover, the rising geriatric population is the key driver for the ophthalmic drugs market growth. According to Safe Eyes America, the most common risk factors for ophthalmic diseases are high age, family history, diabetes, and high blood pressure. For instance, as per AMERICA’s HEALTH RANKINGS senior report 2021 it was estimated that more than 54 million adults of age more than 65 live in the U.S., and that population accounted for 16.5% of the total population. According to Macular Degeneration Research AMD is the leading reason for blindness in U.S. people over the age of 60.
Ongoing regulatory approvals for ophthalmic products are likely to support market growth. For instance, in June 2022 Santen Pharmaceutical Co., Ltd announced that it has got marketing and manufacturing approval for the dry eye disease treatment DIQUAS LX ophthalmic solution in Japan. This solution is the improved formulation that has reduced dosing frequency and improved patient compliance.
Ophthalmic Drugs Market Report Highlights
- Anti-VEGF agents segment held the largest share in 2024 owing to their rising demand and lesser adverse effects
- Retinal disorders held the largest market share in 2024 owing to the rising prevalence of age-related macular degeneration and diabetic retinopathy
- The topical route of administration dominated the market in 2024 owing to factors such as the benefits of the topical route as it delivers the drug to the targeted site and ease of use
- The eye drops segment is expected to hold the largest share in 2024 owing to rising demand for eye drops, high patient compliance, and availability of OTC products
- Asia Pacific is expected to exhibit the fastest growth over the forecast period due to advancements in healthcare infrastructure, increasing demand for eye products, and a large patient pool
This report addresses:
- Market intelligence to enable effective decision-making.
- Market estimates and forecasts from 2018 to 2030.
- Growth opportunities and trend analyses.
- Segment and regional revenue forecasts for market assessment.
- Competition strategy and market share analysis.
- Product innovation listings for you to stay ahead of the curve.
- COVID-19's impact and how to sustain in this fast-evolving market.
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug class
1.2.2. Disease
1.2.3. Route of administration
1.2.4. Dosage type
1.2.5. Product type
1.2.6. Drug type
1.2.7. Regional scope
1.2.8. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
1.2. Segment Definitions
1.2.1. Drug class
1.2.2. Disease
1.2.3. Route of administration
1.2.4. Dosage type
1.2.5. Product type
1.2.6. Drug type
1.2.7. Regional scope
1.2.8. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug class outlook
2.2.2. Disease outlook
2.2.3. Route of administration outlook
2.2.4. Dosage type outlook
2.2.5. Product type outlook
2.2.6. Drug type outlook
2.2.7. Regional outlook
2.3. Competitive Insights
2.2. Segment Outlook
2.2.1. Drug class outlook
2.2.2. Disease outlook
2.2.3. Route of administration outlook
2.2.4. Dosage type outlook
2.2.5. Product type outlook
2.2.6. Drug type outlook
2.2.7. Regional outlook
2.3. Competitive Insights
Chapter 3. Ophthalmic Drugs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing diseases prevalence
3.2.1.2. String development pipeline
3.2.1.3. Advancements in drug delivery
3.2.2. Market restraint analysis
3.2.2.1. Patent expiry of blockbuster drugs
3.3. Ophthalmic Drugs Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing diseases prevalence
3.2.1.2. String development pipeline
3.2.1.3. Advancements in drug delivery
3.2.2. Market restraint analysis
3.2.2.1. Patent expiry of blockbuster drugs
3.3. Ophthalmic Drugs Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
Chapter 4. Ophthalmic Drugs Market: Drug Class Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Ophthalmic Drugs Market: Drug Class Movement Analysis
4.3. Ophthalmic Drugs Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
4.4. Anti-Allergy
4.4.1. Anti-Allergy market revenue estimates and forecasts, 2018-2030 (USD Million)
4.5. Anti-VEGF agents
4.5.1. Anti-VEGF agents market revenue estimates and forecasts, 2018-2030 (USD Million)
4.6. Anti-inflammatory
4.6.1. Anti-inflammatory market revenue estimates and forecasts, 2018-2030 (USD Million)
4.6.2. Non-steroidal Drugs
4.6.2.1. Non-steroidal Drugs market revenue estimates and forecasts, 2018-2030 (USD Million)
4.6.3. Steroids
4.6.3.1. Steroids market revenue estimates and forecasts, 2018-2030 (USD Million)
4.7. Anti-glaucoma
4.7.1. Anti-glaucoma market revenue estimates and forecasts, 2018-2030 (USD Million)
4.8. Gene & Cell Therapy
4.8.1. Gene & Cell Therapy market revenue estimates and forecasts, 2018-2030 (USD Million)
4.9. Others
4.9.1. Others market revenue estimates and forecasts, 2018-2030 (USD Million)
4.2. Ophthalmic Drugs Market: Drug Class Movement Analysis
4.3. Ophthalmic Drugs Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
4.4. Anti-Allergy
4.4.1. Anti-Allergy market revenue estimates and forecasts, 2018-2030 (USD Million)
4.5. Anti-VEGF agents
4.5.1. Anti-VEGF agents market revenue estimates and forecasts, 2018-2030 (USD Million)
4.6. Anti-inflammatory
4.6.1. Anti-inflammatory market revenue estimates and forecasts, 2018-2030 (USD Million)
4.6.2. Non-steroidal Drugs
4.6.2.1. Non-steroidal Drugs market revenue estimates and forecasts, 2018-2030 (USD Million)
4.6.3. Steroids
4.6.3.1. Steroids market revenue estimates and forecasts, 2018-2030 (USD Million)
4.7. Anti-glaucoma
4.7.1. Anti-glaucoma market revenue estimates and forecasts, 2018-2030 (USD Million)
4.8. Gene & Cell Therapy
4.8.1. Gene & Cell Therapy market revenue estimates and forecasts, 2018-2030 (USD Million)
4.9. Others
4.9.1. Others market revenue estimates and forecasts, 2018-2030 (USD Million)
Chapter 5. Ophthalmic Drugs Market: Disease Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Ophthalmic Drugs Market: Disease Movement Analysis
5.3. Ophthalmic Drugs Market Size & Trend Analysis, by Disease, 2018 to 2030 (USD Million)
5.4. Dry eye
5.4.1. Dry eye market revenue estimates and forecasts, 2018-2030 (USD Million)
5.4.1.1. Gels
5.4.1.1.1. Gels market revenue estimates and forecasts, 2018-2030 (USD Million)
5.4.1.2. Eye solutions & suspensions
5.4.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018-2030 (USD Million)
5.4.1.3. Capsules & tablets
5.4.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018-2030 (USD Million)
5.4.1.4. Eye drops
5.4.1.4.1. Eye drops market revenue estimates and forecasts, 2018-2030 (USD Million)
5.4.1.5. Ointments
5.4.1.5.1. Ointments market revenue estimates and forecasts, 2018-2030 (USD Million)
5.5. Allergies
5.5.1. Allergies market revenue estimates and forecasts, 2018-2030 (USD Million)
5.5.1.1. Gels
5.5.1.1.1. Gels market revenue estimates and forecasts, 2018-2030 (USD Million)
5.5.1.2. Eye solutions & suspensions
5.5.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018-2030 (USD Million)
5.5.1.3. Capsules & tablets
5.5.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018-2030 (USD Million)
5.5.1.4. Eye drops
5.5.1.4.1. Eye drops market revenue estimates and forecasts, 2018-2030 (USD Million)
5.5.1.5. Ointments
5.5.1.5.1. Ointments market revenue estimates and forecasts, 2018-2030 (USD Million)
5.6. Glaucoma
5.6.1. Glaucoma market revenue estimates and forecasts, 2018-2030 (USD Million)
5.6.1.1. Gels
5.6.1.1.1. Gels market revenue estimates and forecasts, 2018-2030 (USD Million)
5.6.1.2. Eye solutions & suspensions
5.6.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018-2030 (USD Million)
5.6.1.3. Capsules & tablets
5.6.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018-2030 (USD Million)
5.6.1.4. Eye drops
5.6.1.4.1. Eye drops market revenue estimates and forecasts, 2018-2030 (USD Million)
5.6.1.5. Ointments
5.6.1.5.1. Ointments market revenue estimates and forecasts, 2018-2030 (USD Million)
5.7. Infection
5.7.1. Infection market revenue estimates and forecasts, 2018-2030 (USD Million)
5.7.1.1. Gels
5.7.1.1.1. Gels market revenue estimates and forecasts, 2018-2030 (USD Million)
5.7.1.2. Eye solutions & suspensions
5.7.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018-2030 (USD Million)
5.7.1.3. Capsules & tablets
5.7.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018-2030 (USD Million)
5.7.1.4. Eye drops
5.7.1.4.1. Eye drops market revenue estimates and forecasts, 2018-2030 (USD Million)
5.7.1.5. Ointments
5.7.1.5.1. Ointments market revenue estimates and forecasts, 2018-2030 (USD Million)
5.8. Retinal Disorders
5.8.1. Retinal disorders market revenue estimates and forecasts, 2018-2030 (USD Million)
5.8.2. By Dosage Type
5.8.2.1. Gels
5.8.2.1.1. Gels market revenue estimates and forecasts, 2018-2030 (USD Million)
5.8.2.2. Eye solutions & suspensions
5.8.2.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018-2030 (USD Million)
5.8.2.3. Capsules & tablets
5.8.2.3.1. Capsules & tablets market revenue estimates and forecasts, 2018-2030 (USD Million)
5.8.2.4. Eye drops
5.8.2.4.1. Eye drops market revenue estimates and forecasts, 2018-2030 (USD Million)
5.8.2.5. Ointments
5.8.2.5.1. Ointments market revenue estimates and forecasts, 2018-2030 (USD Million)
5.8.3. By Type
5.8.3.1. Macular degeneration
5.8.3.1.1. Macular degeneration market revenue estimates and forecasts, 2018-2030 (USD Million)
5.8.3.2. Diabetic retinopathy
5.8.3.2.1. Diabetic retinopathy market revenue estimates and forecasts, 2018-2030 (USD Million)
5.8.3.3. Others
5.8.3.3.1. Others market revenue estimates and forecasts, 2018-2030 (USD Million)
5.9. Uveitis
5.9.1. Uveitis market revenue estimates and forecasts, 2018-2030 (USD Million)
5.9.1.1. Gels
5.9.1.1.1. Gels market revenue estimates and forecasts, 2018-2030 (USD Million)
5.9.1.2. Eye solutions & suspensions
5.9.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018-2030 (USD Million)
5.9.1.3. Capsules & tablets
5.9.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018-2030 (USD Million)
5.9.1.4. Eye drops
5.9.1.4.1. Eye drops market revenue estimates and forecasts, 2018-2030 (USD Million)
5.9.1.5. Ointments
5.9.1.5.1. Ointments market revenue estimates and forecasts, 2018-2030 (USD Million)
5.10. Others
5.10.1. Others market revenue estimates and forecasts, 2018-2030 (USD Million)
5.10.1.1. Gels
5.10.1.1.1. Gels market revenue estimates and forecasts, 2018-2030 (USD Million)
5.10.1.2. Eye solutions & suspensions
5.10.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018-2030 (USD Million)
5.10.1.3. Capsules & tablets
5.10.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018-2030 (USD Million)
5.10.1.4. Eye drops
5.10.1.4.1. Eye drops market revenue estimates and forecasts, 2018-2030 (USD Million)
5.10.1.5. Ointments
5.10.1.5.1. Ointments market revenue estimates and forecasts, 2018-2030 (USD Million)
5.2. Ophthalmic Drugs Market: Disease Movement Analysis
5.3. Ophthalmic Drugs Market Size & Trend Analysis, by Disease, 2018 to 2030 (USD Million)
5.4. Dry eye
5.4.1. Dry eye market revenue estimates and forecasts, 2018-2030 (USD Million)
5.4.1.1. Gels
5.4.1.1.1. Gels market revenue estimates and forecasts, 2018-2030 (USD Million)
5.4.1.2. Eye solutions & suspensions
5.4.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018-2030 (USD Million)
5.4.1.3. Capsules & tablets
5.4.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018-2030 (USD Million)
5.4.1.4. Eye drops
5.4.1.4.1. Eye drops market revenue estimates and forecasts, 2018-2030 (USD Million)
5.4.1.5. Ointments
5.4.1.5.1. Ointments market revenue estimates and forecasts, 2018-2030 (USD Million)
5.5. Allergies
5.5.1. Allergies market revenue estimates and forecasts, 2018-2030 (USD Million)
5.5.1.1. Gels
5.5.1.1.1. Gels market revenue estimates and forecasts, 2018-2030 (USD Million)
5.5.1.2. Eye solutions & suspensions
5.5.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018-2030 (USD Million)
5.5.1.3. Capsules & tablets
5.5.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018-2030 (USD Million)
5.5.1.4. Eye drops
5.5.1.4.1. Eye drops market revenue estimates and forecasts, 2018-2030 (USD Million)
5.5.1.5. Ointments
5.5.1.5.1. Ointments market revenue estimates and forecasts, 2018-2030 (USD Million)
5.6. Glaucoma
5.6.1. Glaucoma market revenue estimates and forecasts, 2018-2030 (USD Million)
5.6.1.1. Gels
5.6.1.1.1. Gels market revenue estimates and forecasts, 2018-2030 (USD Million)
5.6.1.2. Eye solutions & suspensions
5.6.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018-2030 (USD Million)
5.6.1.3. Capsules & tablets
5.6.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018-2030 (USD Million)
5.6.1.4. Eye drops
5.6.1.4.1. Eye drops market revenue estimates and forecasts, 2018-2030 (USD Million)
5.6.1.5. Ointments
5.6.1.5.1. Ointments market revenue estimates and forecasts, 2018-2030 (USD Million)
5.7. Infection
5.7.1. Infection market revenue estimates and forecasts, 2018-2030 (USD Million)
5.7.1.1. Gels
5.7.1.1.1. Gels market revenue estimates and forecasts, 2018-2030 (USD Million)
5.7.1.2. Eye solutions & suspensions
5.7.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018-2030 (USD Million)
5.7.1.3. Capsules & tablets
5.7.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018-2030 (USD Million)
5.7.1.4. Eye drops
5.7.1.4.1. Eye drops market revenue estimates and forecasts, 2018-2030 (USD Million)
5.7.1.5. Ointments
5.7.1.5.1. Ointments market revenue estimates and forecasts, 2018-2030 (USD Million)
5.8. Retinal Disorders
5.8.1. Retinal disorders market revenue estimates and forecasts, 2018-2030 (USD Million)
5.8.2. By Dosage Type
5.8.2.1. Gels
5.8.2.1.1. Gels market revenue estimates and forecasts, 2018-2030 (USD Million)
5.8.2.2. Eye solutions & suspensions
5.8.2.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018-2030 (USD Million)
5.8.2.3. Capsules & tablets
5.8.2.3.1. Capsules & tablets market revenue estimates and forecasts, 2018-2030 (USD Million)
5.8.2.4. Eye drops
5.8.2.4.1. Eye drops market revenue estimates and forecasts, 2018-2030 (USD Million)
5.8.2.5. Ointments
5.8.2.5.1. Ointments market revenue estimates and forecasts, 2018-2030 (USD Million)
5.8.3. By Type
5.8.3.1. Macular degeneration
5.8.3.1.1. Macular degeneration market revenue estimates and forecasts, 2018-2030 (USD Million)
5.8.3.2. Diabetic retinopathy
5.8.3.2.1. Diabetic retinopathy market revenue estimates and forecasts, 2018-2030 (USD Million)
5.8.3.3. Others
5.8.3.3.1. Others market revenue estimates and forecasts, 2018-2030 (USD Million)
5.9. Uveitis
5.9.1. Uveitis market revenue estimates and forecasts, 2018-2030 (USD Million)
5.9.1.1. Gels
5.9.1.1.1. Gels market revenue estimates and forecasts, 2018-2030 (USD Million)
5.9.1.2. Eye solutions & suspensions
5.9.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018-2030 (USD Million)
5.9.1.3. Capsules & tablets
5.9.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018-2030 (USD Million)
5.9.1.4. Eye drops
5.9.1.4.1. Eye drops market revenue estimates and forecasts, 2018-2030 (USD Million)
5.9.1.5. Ointments
5.9.1.5.1. Ointments market revenue estimates and forecasts, 2018-2030 (USD Million)
5.10. Others
5.10.1. Others market revenue estimates and forecasts, 2018-2030 (USD Million)
5.10.1.1. Gels
5.10.1.1.1. Gels market revenue estimates and forecasts, 2018-2030 (USD Million)
5.10.1.2. Eye solutions & suspensions
5.10.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018-2030 (USD Million)
5.10.1.3. Capsules & tablets
5.10.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2018-2030 (USD Million)
5.10.1.4. Eye drops
5.10.1.4.1. Eye drops market revenue estimates and forecasts, 2018-2030 (USD Million)
5.10.1.5. Ointments
5.10.1.5.1. Ointments market revenue estimates and forecasts, 2018-2030 (USD Million)
Chapter 6. Ophthalmic Drugs Market: Route of Administration Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Ophthalmic Drugs Market: Route of Administration Movement Analysis
6.3. Ophthalmic Drugs Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Topical
6.4.1. Topical market revenue estimates and forecasts, 2018-2030 (USD Million)
6.5. Local Ocular
6.5.1. Local ocular market revenue estimates and forecasts, 2018-2030 (USD Million)
6.5.1.1. Subconjunctival
6.5.1.1.1. Subconjunctival market revenue estimates and forecasts, 2018-2030 (USD Million)
6.5.1.2. Intravitreal
6.5.1.2.1. Intravitreal market revenue estimates and forecasts, 2018-2030 (USD Million)
6.5.1.3. Retrobulbar
6.5.1.3.1. Retrobulbar market revenue estimates and forecasts, 2018-2030 (USD Million)
6.5.1.4. Intracameral
6.5.1.4.1. Intracameral market revenue estimates and forecasts, 2018-2030 (USD Million)
6.6. Sytemic
6.6.1. Sytemic market revenue estimates and forecasts, 2018-2030 (USD Million)
6.2. Ophthalmic Drugs Market: Route of Administration Movement Analysis
6.3. Ophthalmic Drugs Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Topical
6.4.1. Topical market revenue estimates and forecasts, 2018-2030 (USD Million)
6.5. Local Ocular
6.5.1. Local ocular market revenue estimates and forecasts, 2018-2030 (USD Million)
6.5.1.1. Subconjunctival
6.5.1.1.1. Subconjunctival market revenue estimates and forecasts, 2018-2030 (USD Million)
6.5.1.2. Intravitreal
6.5.1.2.1. Intravitreal market revenue estimates and forecasts, 2018-2030 (USD Million)
6.5.1.3. Retrobulbar
6.5.1.3.1. Retrobulbar market revenue estimates and forecasts, 2018-2030 (USD Million)
6.5.1.4. Intracameral
6.5.1.4.1. Intracameral market revenue estimates and forecasts, 2018-2030 (USD Million)
6.6. Sytemic
6.6.1. Sytemic market revenue estimates and forecasts, 2018-2030 (USD Million)
Chapter 7. Ophthalmic Drugs Market: Dosage Type Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Ophthalmic Drugs Market: Dosage Type Movement Analysis
7.3. Ophthalmic Drugs Market Size & Trend Analysis, by Dosage Type, 2018 to 2030 (USD Million)
7.4. Gels
7.4.1. Gels market revenue estimates and forecasts, 2018-2030 (USD Million)
7.5. Eye solutions & suspensions
7.5.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018-2030 (USD Million)
7.6. Capsules & Tablets
7.6.1. Capsules & tablets market revenue estimates and forecasts, 2018-2030 (USD Million)
7.7. Eye drops
7.7.1. Eye drops market revenue estimates and forecasts, 2018-2030 (USD Million)
7.8. Ointments
7.8.1. Ointments market revenue estimates and forecasts, 2018-2030 (USD Million)
7.2. Ophthalmic Drugs Market: Dosage Type Movement Analysis
7.3. Ophthalmic Drugs Market Size & Trend Analysis, by Dosage Type, 2018 to 2030 (USD Million)
7.4. Gels
7.4.1. Gels market revenue estimates and forecasts, 2018-2030 (USD Million)
7.5. Eye solutions & suspensions
7.5.1. Eye solutions & suspensions market revenue estimates and forecasts, 2018-2030 (USD Million)
7.6. Capsules & Tablets
7.6.1. Capsules & tablets market revenue estimates and forecasts, 2018-2030 (USD Million)
7.7. Eye drops
7.7.1. Eye drops market revenue estimates and forecasts, 2018-2030 (USD Million)
7.8. Ointments
7.8.1. Ointments market revenue estimates and forecasts, 2018-2030 (USD Million)
Chapter 8. Ophthalmic Drugs Market: Product Type Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Ophthalmic Drugs Market: Product Type Movement Analysis
8.3. Ophthalmic Drugs Market Size & Trend Analysis, by Product Type, 2018 to 2030 (USD Million)
8.4. OTC
8.4.1. OTC market revenue estimates and forecasts, 2018-2030 (USD Million)
8.5. Prescription Drugs
8.5.1. Prescription drugs market revenue estimates and forecasts, 2018-2030 (USD Million)
8.2. Ophthalmic Drugs Market: Product Type Movement Analysis
8.3. Ophthalmic Drugs Market Size & Trend Analysis, by Product Type, 2018 to 2030 (USD Million)
8.4. OTC
8.4.1. OTC market revenue estimates and forecasts, 2018-2030 (USD Million)
8.5. Prescription Drugs
8.5.1. Prescription drugs market revenue estimates and forecasts, 2018-2030 (USD Million)
Chapter 9. Ophthalmic Drugs Market: Drug Type Estimates & Trend Analysis
9.1. Segment Dashboard
9.2. Ophthalmic Drugs Market: Drug Type Movement Analysis
9.3. Ophthalmic Drugs Market Size & Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
9.4. Branded Drugs
9.4.1. Branded drugs market revenue estimates and forecasts, 2018-2030 (USD Million)
9.5. Generic Drugs
9.5.1. Generic drugs market revenue estimates and forecasts, 2018-2030 (USD Million)
9.2. Ophthalmic Drugs Market: Drug Type Movement Analysis
9.3. Ophthalmic Drugs Market Size & Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
9.4. Branded Drugs
9.4.1. Branded drugs market revenue estimates and forecasts, 2018-2030 (USD Million)
9.5. Generic Drugs
9.5.1. Generic drugs market revenue estimates and forecasts, 2018-2030 (USD Million)
Chapter 10. Ophthalmic Drugs Market: Regional Estimates & Trend Analysis
10.1. Regional Market Share Analysis, 2023 & 2030
10.2. Regional Market Dashboard
10.3. Global Regional Market Snapshot
10.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
10.5. North America
10.5.1. U.S.
10.5.1.1. Key country dynamics
10.5.1.2. Regulatory framework/Reimbursement
10.5.1.3. Competitive scenario
10.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
10.5.2. Canada
10.5.2.1. Key country dynamics
10.5.2.2. Regulatory framework/Reimbursement
10.5.2.3. Competitive scenario
10.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
10.5.3. Mexico
10.5.3.1. Key country dynamics
10.5.3.2. Regulatory framework/Reimbursement
10.5.3.3. Competitive scenario
10.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
10.6. Europe
10.6.1. UK
10.6.1.1. Key country dynamics
10.6.1.2. Regulatory framework/Reimbursement
10.6.1.3. Competitive scenario
10.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
10.6.2. Germany
10.6.2.1. Key country dynamics
10.6.2.2. Regulatory framework/Reimbursement
10.6.2.3. Competitive scenario
10.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
10.6.3. France
10.6.3.1. Key country dynamics
10.6.3.2. Regulatory framework/Reimbursement
10.6.3.3. Competitive scenario
10.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
10.6.4. Italy
10.6.4.1. Key country dynamics
10.6.4.2. Regulatory framework/Reimbursement
10.6.4.3. Competitive scenario
10.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
10.6.5. Spain
10.6.5.1. Key country dynamics
10.6.5.2. Regulatory framework/Reimbursement
10.6.5.3. Competitive scenario
10.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
10.6.6. Norway
10.6.6.1. Key country dynamics
10.6.6.2. Regulatory framework/Reimbursement
10.6.6.3. Competitive scenario
10.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
10.6.7. Sweden
10.6.7.1. Key country dynamics
10.6.7.2. Regulatory framework/Reimbursement
10.6.7.3. Competitive scenario
10.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
10.6.8. Denmark
10.6.8.1. Key country dynamics
10.6.8.2. Regulatory framework/Reimbursement
10.6.8.3. Competitive scenario
10.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
10.7. Asia Pacific
10.7.1. Japan
10.7.1.1. Key country dynamics
10.7.1.2. Regulatory framework/Reimbursement
10.7.1.3. Competitive scenario
10.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
10.7.2. China
10.7.2.1. Key country dynamics
10.7.2.2. Regulatory framework/Reimbursement
10.7.2.3. Competitive scenario
10.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
10.7.3. India
10.7.3.1. Key country dynamics
10.7.3.2. Regulatory framework/Reimbursement
10.7.3.3. Competitive scenario
10.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
10.7.4. Australia
10.7.4.1. Key country dynamics
10.7.4.2. Regulatory framework/Reimbursement
10.7.4.3. Competitive scenario
10.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
10.7.5. South Korea
10.7.5.1. Key country dynamics
10.7.5.2. Regulatory framework/Reimbursement
10.7.5.3. Competitive scenario
10.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
10.7.6. Thailand
10.7.6.1. Key country dynamics
10.7.6.2. Regulatory framework/Reimbursement
10.7.6.3. Competitive scenario
10.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
10.8. Latin America
10.8.1. Brazil
10.8.1.1. Key country dynamics
10.8.1.2. Regulatory framework/Reimbursement
10.8.1.3. Competitive scenario
10.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
10.8.2. Argentina
10.8.2.1. Key country dynamics
10.8.2.2. Regulatory framework/Reimbursement
10.8.2.3. Competitive scenario
10.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
10.9. MEA
10.9.1. South Africa
10.9.1.1. Key country dynamics
10.9.1.2. Regulatory framework/Reimbursement
10.9.1.3. Competitive scenario
10.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
10.9.2. Saudi Arabia
10.9.2.1. Key country dynamics
10.9.2.2. Regulatory framework/Reimbursement
10.9.2.3. Competitive scenario
10.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
10.9.3. UAE
10.9.3.1. Key country dynamics
10.9.3.2. Regulatory framework/Reimbursement
10.9.3.3. Competitive scenario
10.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
10.9.4. Kuwait
10.9.4.1. Key country dynamics
10.9.4.2. Regulatory framework
10.9.4.3. Competitive scenario
10.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
10.2. Regional Market Dashboard
10.3. Global Regional Market Snapshot
10.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
10.5. North America
10.5.1. U.S.
10.5.1.1. Key country dynamics
10.5.1.2. Regulatory framework/Reimbursement
10.5.1.3. Competitive scenario
10.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
10.5.2. Canada
10.5.2.1. Key country dynamics
10.5.2.2. Regulatory framework/Reimbursement
10.5.2.3. Competitive scenario
10.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
10.5.3. Mexico
10.5.3.1. Key country dynamics
10.5.3.2. Regulatory framework/Reimbursement
10.5.3.3. Competitive scenario
10.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
10.6. Europe
10.6.1. UK
10.6.1.1. Key country dynamics
10.6.1.2. Regulatory framework/Reimbursement
10.6.1.3. Competitive scenario
10.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
10.6.2. Germany
10.6.2.1. Key country dynamics
10.6.2.2. Regulatory framework/Reimbursement
10.6.2.3. Competitive scenario
10.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
10.6.3. France
10.6.3.1. Key country dynamics
10.6.3.2. Regulatory framework/Reimbursement
10.6.3.3. Competitive scenario
10.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
10.6.4. Italy
10.6.4.1. Key country dynamics
10.6.4.2. Regulatory framework/Reimbursement
10.6.4.3. Competitive scenario
10.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
10.6.5. Spain
10.6.5.1. Key country dynamics
10.6.5.2. Regulatory framework/Reimbursement
10.6.5.3. Competitive scenario
10.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
10.6.6. Norway
10.6.6.1. Key country dynamics
10.6.6.2. Regulatory framework/Reimbursement
10.6.6.3. Competitive scenario
10.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
10.6.7. Sweden
10.6.7.1. Key country dynamics
10.6.7.2. Regulatory framework/Reimbursement
10.6.7.3. Competitive scenario
10.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
10.6.8. Denmark
10.6.8.1. Key country dynamics
10.6.8.2. Regulatory framework/Reimbursement
10.6.8.3. Competitive scenario
10.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
10.7. Asia Pacific
10.7.1. Japan
10.7.1.1. Key country dynamics
10.7.1.2. Regulatory framework/Reimbursement
10.7.1.3. Competitive scenario
10.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
10.7.2. China
10.7.2.1. Key country dynamics
10.7.2.2. Regulatory framework/Reimbursement
10.7.2.3. Competitive scenario
10.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
10.7.3. India
10.7.3.1. Key country dynamics
10.7.3.2. Regulatory framework/Reimbursement
10.7.3.3. Competitive scenario
10.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
10.7.4. Australia
10.7.4.1. Key country dynamics
10.7.4.2. Regulatory framework/Reimbursement
10.7.4.3. Competitive scenario
10.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
10.7.5. South Korea
10.7.5.1. Key country dynamics
10.7.5.2. Regulatory framework/Reimbursement
10.7.5.3. Competitive scenario
10.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
10.7.6. Thailand
10.7.6.1. Key country dynamics
10.7.6.2. Regulatory framework/Reimbursement
10.7.6.3. Competitive scenario
10.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
10.8. Latin America
10.8.1. Brazil
10.8.1.1. Key country dynamics
10.8.1.2. Regulatory framework/Reimbursement
10.8.1.3. Competitive scenario
10.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
10.8.2. Argentina
10.8.2.1. Key country dynamics
10.8.2.2. Regulatory framework/Reimbursement
10.8.2.3. Competitive scenario
10.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
10.9. MEA
10.9.1. South Africa
10.9.1.1. Key country dynamics
10.9.1.2. Regulatory framework/Reimbursement
10.9.1.3. Competitive scenario
10.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
10.9.2. Saudi Arabia
10.9.2.1. Key country dynamics
10.9.2.2. Regulatory framework/Reimbursement
10.9.2.3. Competitive scenario
10.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
10.9.3. UAE
10.9.3.1. Key country dynamics
10.9.3.2. Regulatory framework/Reimbursement
10.9.3.3. Competitive scenario
10.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
10.9.4. Kuwait
10.9.4.1. Key country dynamics
10.9.4.2. Regulatory framework
10.9.4.3. Competitive scenario
10.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 11. Competitive Landscape
11.1. Recent Developments & Impact Analysis, by Key Market Participants
11.2. Company/Competition Categorization
11.3. Vendor Landscape
11.3.1. List of key distributors and channel partners
11.3.2. Key customers
11.3.3. Key company market share analysis, 2023
11.3.4. Alcon
11.3.4.1. Company overview
11.3.4.2. Financial performance
11.3.4.3. Services benchmarking
11.3.4.4. Strategic initiatives
11.3.5. Novartis AG
11.3.5.1. Company overview
11.3.5.2. Financial performance
11.3.5.3. Services benchmarking
11.3.5.4. Strategic initiatives
11.3.6. Bausch Health Companies, Inc.
11.3.6.1. Company overview
11.3.6.2. Financial performance
11.3.6.3. Services benchmarking
11.3.6.4. Strategic initiatives
11.3.7. Merck & Co., Inc.
11.3.7.1. Company overview
11.3.7.2. Financial performance
11.3.7.3. Services benchmarking
11.3.7.4. Strategic initiatives
11.3.8. Regeneron Pharmaceuticals, Inc.
11.3.8.1. Company overview
11.3.8.2. Financial performance
11.3.8.3. Services benchmarking
11.3.8.4. Strategic initiatives
11.3.9. Coherus BioSciences, Inc.
11.3.9.1. Company overview
11.3.9.2. Financial performance
11.3.9.3. Services benchmarking
11.3.9.4. Strategic initiatives
11.3.10. AbbVie, Inc. (Allergan)
11.3.10.1. Company overview
11.3.10.2. Financial performance
11.3.10.3. Services benchmarking
11.3.10.4. Strategic initiatives
11.3.11. Pfizer, Inc.
11.3.11.1. Company overview
11.3.11.2. Financial performance
11.3.11.3. Services benchmarking
11.3.11.4. Strategic initiatives
11.3.12. Bayer AG
11.3.12.1. Company overview
11.3.12.2. Financial performance
11.3.12.3. Services benchmarking
11.3.12.4. Strategic initiatives
11.3.13. Santen Pharmaceutical Co., Ltd.
11.3.13.1. Company overview
11.3.13.2. Financial performance
11.3.13.3. Services benchmarking
11.3.13.4. Strategic initiatives
11.3.14. Roche (Genentech, Inc.)
11.3.14.1. Company overview
11.3.14.2. Financial performance
11.3.14.3. Services benchmarking
11.3.14.4. Strategic initiatives
11.3.15. Nicox
11.3.15.1. Company overview
11.3.15.2. Financial performance
11.3.15.3. Services benchmarking
11.3.15.4. Strategic initiatives
11.2. Company/Competition Categorization
11.3. Vendor Landscape
11.3.1. List of key distributors and channel partners
11.3.2. Key customers
11.3.3. Key company market share analysis, 2023
11.3.4. Alcon
11.3.4.1. Company overview
11.3.4.2. Financial performance
11.3.4.3. Services benchmarking
11.3.4.4. Strategic initiatives
11.3.5. Novartis AG
11.3.5.1. Company overview
11.3.5.2. Financial performance
11.3.5.3. Services benchmarking
11.3.5.4. Strategic initiatives
11.3.6. Bausch Health Companies, Inc.
11.3.6.1. Company overview
11.3.6.2. Financial performance
11.3.6.3. Services benchmarking
11.3.6.4. Strategic initiatives
11.3.7. Merck & Co., Inc.
11.3.7.1. Company overview
11.3.7.2. Financial performance
11.3.7.3. Services benchmarking
11.3.7.4. Strategic initiatives
11.3.8. Regeneron Pharmaceuticals, Inc.
11.3.8.1. Company overview
11.3.8.2. Financial performance
11.3.8.3. Services benchmarking
11.3.8.4. Strategic initiatives
11.3.9. Coherus BioSciences, Inc.
11.3.9.1. Company overview
11.3.9.2. Financial performance
11.3.9.3. Services benchmarking
11.3.9.4. Strategic initiatives
11.3.10. AbbVie, Inc. (Allergan)
11.3.10.1. Company overview
11.3.10.2. Financial performance
11.3.10.3. Services benchmarking
11.3.10.4. Strategic initiatives
11.3.11. Pfizer, Inc.
11.3.11.1. Company overview
11.3.11.2. Financial performance
11.3.11.3. Services benchmarking
11.3.11.4. Strategic initiatives
11.3.12. Bayer AG
11.3.12.1. Company overview
11.3.12.2. Financial performance
11.3.12.3. Services benchmarking
11.3.12.4. Strategic initiatives
11.3.13. Santen Pharmaceutical Co., Ltd.
11.3.13.1. Company overview
11.3.13.2. Financial performance
11.3.13.3. Services benchmarking
11.3.13.4. Strategic initiatives
11.3.14. Roche (Genentech, Inc.)
11.3.14.1. Company overview
11.3.14.2. Financial performance
11.3.14.3. Services benchmarking
11.3.14.4. Strategic initiatives
11.3.15. Nicox
11.3.15.1. Company overview
11.3.15.2. Financial performance
11.3.15.3. Services benchmarking
11.3.15.4. Strategic initiatives
List of Tables
Table 1 List of abbreviations
Table 2 North America ophthalmic drugs market, by region, 2018-2030 (USD Million)
Table 3 North America ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 4 North America ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 5 North America ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 6 North America ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 7 North America ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 8 North America ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 9 U.S. ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 10 U.S. ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 11 U.S. ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 12 U.S. ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 13 U.S. ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 14 U.S. ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 15 Canada ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 16 Canada ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 17 Canada ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 18 Canada ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 19 Canada ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 20 Canada ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 21 Mexico ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 22 Mexico ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 23 Mexico ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 24 Mexico ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 25 Mexico ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 26 Mexico ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 27 Europe ophthalmic drugs market, by region, 2018-2030 (USD Million)
Table 28 Europe ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 29 Europe ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 30 Europe ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 31 Europe ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 32 Europe ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 33 Europe ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 34 UK ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 35 UK ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 36 UK ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 37 UK ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 38 UK ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 39 UK ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 40 Germany ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 41 Germany ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 42 Germany ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 43 Germany ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 44 Germany ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 45 Germany ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 46 France ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 47 France ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 48 France ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 49 France ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 50 France ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 51 France ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 52 Italy ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 53 Italy ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 54 Italy ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 55 Italy ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 56 Italy ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 57 Italy ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 58 Spain ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 59 Spain ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 60 Spain ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 61 Spain ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 62 Spain ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 63 Spain ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 64 Denmark ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 65 Denmark ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 66 Denmark ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 67 Denmark ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 68 Denmark ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 69 Denmark ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 70 Sweden ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 71 Sweden ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 72 Sweden ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 73 Sweden ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 74 Sweden ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 75 Sweden ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 76 Norway ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 77 Norway ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 78 Norway ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 79 Norway ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 80 Norway ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 81 Norway ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 82 Asia Pacific ophthalmic drugs market, by region, 2018-2030 (USD Million)
Table 83 Asia Pacific ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 84 Asia Pacific ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 85 Asia Pacific ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 86 Asia Pacific ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 87 Asia Pacific ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 88 China ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 89 China ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 90 China ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 91 China ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 92 China ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 93 China ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 94 Japan ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 95 Japan ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 96 Japan ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 97 Japan ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 98 Japan ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 99 Japan ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 100 India ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 101 India ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 102 India ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 103 India ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 104 India ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 105 India ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 106 Australia ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 107 Australia ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 108 Australia ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 109 Australia ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 110 Australia ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 111 Australia ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 112 South Korea ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 113 South Korea ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 114 South Korea ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 115 South Korea ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 116 South Korea ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 117 South Korea ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 118 Thailand ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 119 Thailand ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 120 Thailand ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 121 Thailand ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 122 Thailand ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 123 Thailand ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 124 Latin America ophthalmic drugs market, by region, 2018-2030 (USD Million)
Table 125 Latin America ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 126 Latin America ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 127 Latin America ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 128 Latin America ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 129 Latin America ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 130 Latin America ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 131 Brazil ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 132 Brazil ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 133 Brazil ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 134 Brazil ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 135 Brazil ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 136 Brazil ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 137 Argentina ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 138 Argentina ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 139 Argentina ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 140 Argentina ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 141 Argentina ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 142 Argentina ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 143 MEA ophthalmic drugs market, by region, 2018-2030 (USD Million)
Table 144 MEA ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 145 MEA ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 146 MEA ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 147 MEA ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 148 MEA ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 149 MEA ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 150 South Africa ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 151 South Africa ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 152 South Africa ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 153 South Africa ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 154 South Africa ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 155 South Africa ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 156 Saudi Arabia ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 157 Saudi Arabia ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 158 Saudi Arabia ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 159 Saudi Arabia ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 160 Saudi Arabia ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 161 Saudi Arabia ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 162 UAE ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 163 UAE ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 164 UAE ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 165 UAE ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 166 UAE ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 167 UAE ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 168 Kuwait ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 169 Kuwait ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 170 Kuwait ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 171 Kuwait ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 172 Kuwait ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 173 Kuwait ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 2 North America ophthalmic drugs market, by region, 2018-2030 (USD Million)
Table 3 North America ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 4 North America ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 5 North America ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 6 North America ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 7 North America ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 8 North America ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 9 U.S. ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 10 U.S. ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 11 U.S. ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 12 U.S. ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 13 U.S. ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 14 U.S. ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 15 Canada ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 16 Canada ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 17 Canada ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 18 Canada ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 19 Canada ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 20 Canada ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 21 Mexico ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 22 Mexico ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 23 Mexico ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 24 Mexico ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 25 Mexico ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 26 Mexico ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 27 Europe ophthalmic drugs market, by region, 2018-2030 (USD Million)
Table 28 Europe ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 29 Europe ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 30 Europe ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 31 Europe ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 32 Europe ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 33 Europe ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 34 UK ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 35 UK ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 36 UK ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 37 UK ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 38 UK ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 39 UK ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 40 Germany ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 41 Germany ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 42 Germany ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 43 Germany ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 44 Germany ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 45 Germany ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 46 France ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 47 France ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 48 France ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 49 France ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 50 France ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 51 France ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 52 Italy ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 53 Italy ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 54 Italy ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 55 Italy ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 56 Italy ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 57 Italy ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 58 Spain ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 59 Spain ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 60 Spain ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 61 Spain ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 62 Spain ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 63 Spain ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 64 Denmark ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 65 Denmark ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 66 Denmark ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 67 Denmark ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 68 Denmark ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 69 Denmark ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 70 Sweden ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 71 Sweden ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 72 Sweden ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 73 Sweden ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 74 Sweden ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 75 Sweden ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 76 Norway ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 77 Norway ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 78 Norway ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 79 Norway ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 80 Norway ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 81 Norway ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 82 Asia Pacific ophthalmic drugs market, by region, 2018-2030 (USD Million)
Table 83 Asia Pacific ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 84 Asia Pacific ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 85 Asia Pacific ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 86 Asia Pacific ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 87 Asia Pacific ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 88 China ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 89 China ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 90 China ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 91 China ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 92 China ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 93 China ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 94 Japan ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 95 Japan ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 96 Japan ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 97 Japan ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 98 Japan ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 99 Japan ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 100 India ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 101 India ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 102 India ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 103 India ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 104 India ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 105 India ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 106 Australia ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 107 Australia ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 108 Australia ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 109 Australia ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 110 Australia ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 111 Australia ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 112 South Korea ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 113 South Korea ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 114 South Korea ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 115 South Korea ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 116 South Korea ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 117 South Korea ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 118 Thailand ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 119 Thailand ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 120 Thailand ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 121 Thailand ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 122 Thailand ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 123 Thailand ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 124 Latin America ophthalmic drugs market, by region, 2018-2030 (USD Million)
Table 125 Latin America ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 126 Latin America ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 127 Latin America ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 128 Latin America ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 129 Latin America ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 130 Latin America ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 131 Brazil ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 132 Brazil ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 133 Brazil ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 134 Brazil ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 135 Brazil ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 136 Brazil ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 137 Argentina ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 138 Argentina ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 139 Argentina ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 140 Argentina ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 141 Argentina ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 142 Argentina ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 143 MEA ophthalmic drugs market, by region, 2018-2030 (USD Million)
Table 144 MEA ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 145 MEA ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 146 MEA ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 147 MEA ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 148 MEA ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 149 MEA ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 150 South Africa ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 151 South Africa ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 152 South Africa ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 153 South Africa ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 154 South Africa ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 155 South Africa ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 156 Saudi Arabia ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 157 Saudi Arabia ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 158 Saudi Arabia ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 159 Saudi Arabia ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 160 Saudi Arabia ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 161 Saudi Arabia ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 162 UAE ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 163 UAE ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 164 UAE ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 165 UAE ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 166 UAE ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 167 UAE ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
Table 168 Kuwait ophthalmic drugs market, by drug class, 2018-2030 (USD Million)
Table 169 Kuwait ophthalmic drugs market, by disease, 2018-2030 (USD Million)
Table 170 Kuwait ophthalmic drugs market, by route of administration, 2018-2030 (USD Million)
Table 171 Kuwait ophthalmic drugs market, by dosage type, 2018-2030 (USD Million)
Table 172 Kuwait ophthalmic drugs market, by product type, 2018-2030 (USD Million)
Table 173 Kuwait ophthalmic drugs market, by drug type, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Primary interviews in North America
Figure 5 Primary interviews in Europe
Figure 6 Primary interviews in APAC
Figure 7 Primary interviews in Latin America
Figure 8 Primary interviews in MEA
Figure 9 Market research approaches
Figure 10 Value-chain-based sizing & forecasting
Figure 11 QFD modeling for market share assessment
Figure 12 Market formulation & validation
Figure 13 Ophthalmic drugs market: market outlook
Figure 14 Ophthalmic drugs competitive insights
Figure 15 Parent market outlook
Figure 16 Related/ancillary market outlook
Figure 17 Penetration and growth prospect mapping
Figure 18 Industry value chain analysis
Figure 19 Ophthalmic drugs market driver impact
Figure 20 Ophthalmic drugs market restraint impact
Figure 21 Ophthalmic drugs market strategic initiatives analysis
Figure 22 Ophthalmic drugs market: Drug class movement analysis
Figure 23 Ophthalmic drugs market: Drug class outlook and key takeaways
Figure 24 Anti-Allergy market estimates and forecasts, 2018-2030
Figure 25 Anti-VEGF agents market estimates and forecasts, 2018-2030
Figure 26 Anti-inflammatory market estimates and forecasts, 2018-2030
Figure 27 Non steroidal drugs market estimates and forecasts, 2018-2030
Figure 28 Steroidal drugs market estimates and forecasts, 2018-2030
Figure 29 Anti glaucoma market estimates and forecasts, 2018-2030
Figure 30 Gene & cell therapy market estimates and forecasts, 2018-2030
Figure 31 Others market estimates and forecasts, 2018-2030
Figure 32 Ophthalmic drugs market: Disease movement analysis
Figure 33 Ophthalmic drugs market: Disease outlook and key takeaways
Figure 34 Dry eye market estimates and forecasts, 2018-2030
Figure 35 Gels market estimates and forecasts, 2018-2030
Figure 36 Eye solutions & suspensions market estimates and forecasts, 2018-2030
Figure 37 Capsules & tablets market estimates and forecasts, 2018-2030
Figure 38 Eye drops market estimates and forecasts, 2018-2030
Figure 39 Ointments market estimates and forecasts, 2018-2030
Figure 40 Allergies market estimates and forecasts, 2018-2030
Figure 41 Gels market estimates and forecasts, 2018-2030
Figure 42 Eye solutions & suspensions market estimates and forecasts, 2018-2030
Figure 43 Capsules & tablets market estimates and forecasts, 2018-2030
Figure 44 Eye drops market estimates and forecasts, 2018-2030
Figure 45 Ointments market estimates and forecasts, 2018-2030
Figure 46 Glaucoma market estimates and forecasts, 2018-2030
Figure 47 Gels market estimates and forecasts, 2018-2030
Figure 48 Eye solutions & suspensions market estimates and forecasts, 2018-2030
Figure 49 Capsules & tablets market estimates and forecasts, 2018-2030
Figure 50 Eye drops market estimates and forecasts, 2018-2030
Figure 51 Ointments market estimates and forecasts, 2018-2030
Figure 52 Infection market estimates and forecasts, 2018-2030
Figure 53 Gels market estimates and forecasts, 2018-2030
Figure 54 Eye solutions & suspensions market estimates and forecasts, 2018-2030
Figure 55 Capsules & tablets market estimates and forecasts, 2018-2030
Figure 56 Eye drops market estimates and forecasts, 2018-2030
Figure 57 Ointments market estimates and forecasts, 2018-2030
Figure 58 Retinal disorders market estimates and forecasts, 2018-2030
Figure 59 By type market estimates and forecasts, 2018-2030
Figure 60 Macular degeneration market estimates and forecasts, 2018-2030
Figure 61 Diabetic retinopathy market estimates and forecasts, 2018-2030
Figure 62 Others market estimates and forecasts, 2018-2030
Figure 63 By dosage type market estimates and forecasts, 2018-2030
Figure 64 Gels market estimates and forecasts, 2018-2030
Figure 65 Eye solutions & suspensions market estimates and forecasts, 2018-2030
Figure 66 Capsules & tablets market estimates and forecasts, 2018-2030
Figure 67 Eye drops market estimates and forecasts, 2018-2030
Figure 68 Ointments market estimates and forecasts, 2018-2030
Figure 69 Uveitis market estimates and forecasts, 2018-2030
Figure 70 Gels market estimates and forecasts, 2018-2030
Figure 71 Eye solutions & suspensions market estimates and forecasts, 2018-2030
Figure 72 Capsules & tablets market estimates and forecasts, 2018-2030
Figure 73 Eye drops market estimates and forecasts, 2018-2030
Figure 74 Ointments market estimates and forecasts, 2018-2030
Figure 75 Others market estimates and forecasts, 2018-2030
Figure 76 Gels market estimates and forecasts, 2018-2030
Figure 77 Eye solutions & suspensions market estimates and forecasts, 2018-2030
Figure 78 Capsules & tablets market estimates and forecasts, 2018-2030
Figure 79 Eye drops market estimates and forecasts, 2018-2030
Figure 80 Ointments market estimates and forecasts, 2018-2030
Figure 81 Ophthalmic drugs market: Dosage type movement analysis
Figure 82 Ophthalmic drugs market: Dosage type outlook and key takeaways
Figure 83 Gels market estimates and forecasts, 2018-2030
Figure 84 Eye solutions & suspensions market estimates and forecasts, 2018-2030
Figure 85 Capsules & tablets market estimates and forecasts, 2018-2030
Figure 86 Eye drops market estimates and forecasts, 2018-2030
Figure 87 Ointments market estimates and forecasts, 2018-2030
Figure 88 Ophthalmic drugs market: Route of administration movement analysis
Figure 89 Ophthalmic drugs market: Route of administration outlook and key takeaways
Figure 90 Topical market estimates and forecasts, 2018-2030
Figure 91 Local Ocular market estimates and forecasts, 2018-2030
Figure 92 Subconjunctival market estimates and forecasts, 2018-2030
Figure 93 Intravitreal market estimates and forecasts, 2018-2030
Figure 94 Retrobulbar market estimates and forecasts, 2018-2030
Figure 95 Intracameral market estimates and forecasts, 2018-2030
Figure 96 Sytemic market estimates and forecasts, 2018-2030
Figure 97 Ophthalmic drugs market: Product type movement analysis
Figure 98 Ophthalmic drugs market: Product type outlook and key takeaways
Figure 99 OTC market estimates and forecasts, 2018-2030
Figure 100 Prescription drugs market estimates and forecasts, 2018-2030
Figure 101 Ophthalmic drugs market: Drug type movement analysis
Figure 102 Ophthalmic drugs market: Drug type outlook and key takeaways
Figure 103 Branded drugs market estimates and forecasts, 2018-2030
Figure 104 Generic drugs market estimates and forecasts, 2018-2030
Figure 105 Global ophthalmic drugs market: Regional movement analysis
Figure 106 Global ophthalmic drugs market: Regional outlook and key takeaways
Figure 107 Global ophthalmic drugs market share and leading players
Figure 108 North America market share and leading players
Figure 109 Europe market share and leading players
Figure 110 Asia Pacific market share and leading players
Figure 111 Latin America market share and leading players
Figure 112 Middle East & Africa market share and leading players
Figure 113 North America, by country
Figure 114 North America
Figure 115 North America market estimates and forecasts, 2018-2030
Figure 116 U.S. key country dynamics
Figure 117 U.S. market estimates and forecasts, 2018-2030
Figure 118 Canada country dynamics
Figure 119 Canada market estimates and forecasts, 2018-2030
Figure 120 Mexico country dynamics
Figure 121 Mexico market estimates and forecasts, 2018-2030
Figure 122 Europe
Figure 123 Europe market estimates and forecasts, 2018-2030
Figure 124 UK country dynamics
Figure 125 UK market estimates and forecasts, 2018-2030
Figure 126 Germany
Figure 127 Germany market estimates and forecasts, 2018-2030
Figure 128 France country dynamics
Figure 129 France market estimates and forecasts, 2018-2030
Figure 130 Italy country dynamics
Figure 131 Italy market estimates and forecasts, 2018-2030
Figure 132 Spain country dynamics
Figure 133 Spain market estimates and forecasts, 2018-2030
Figure 134 Denmark country dynamics
Figure 135 Denmark market estimates and forecasts, 2018-2030
Figure 136 Sweden country dynamics
Figure 137 Sweden market estimates and forecasts, 2018-2030
Figure 138 Norway country dynamics
Figure 139 Norway market estimates and forecasts, 2018-2030
Figure 140 Asia Pacific
Figure 141 Asia Pacific market estimates and forecasts, 2018-2030
Figure 142 China country dynamics
Figure 143 China market estimates and forecasts, 2018-2030
Figure 144 Japan country dynamics
Figure 145 Japan market estimates and forecasts, 2018-2030
Figure 146 India country dynamics
Figure 147 India market estimates and forecasts, 2018-2030
Figure 148 Thailand country dynamics
Figure 149 Thailand market estimates and forecasts, 2018-2030
Figure 150 South Korea country dynamics
Figure 151 South Korea market estimates and forecasts, 2018-2030
Figure 152 Australia country dynamics
Figure 153 Australia market estimates and forecasts, 2018-2030
Figure 154 Latin America
Figure 155 Latin America market estimates and forecasts, 2018-2030
Figure 156 Brazil country dynamics
Figure 157 Brazil market estimates and forecasts, 2018-2030
Figure 158 Argentina country dynamics
Figure 159 Argentina market estimates and forecasts, 2018-2030
Figure 160 Middle East and Africa
Figure 161 Middle East and Africa market estimates and forecasts, 2018-2030
Figure 162 South Africa country dynamics
Figure 163 South Africa market estimates and forecasts, 2018-2030
Figure 164 Saudi Arabia country dynamics
Figure 165 Saudi Arabia market estimates and forecasts, 2018-2030
Figure 166 UAE country dynamics
Figure 167 UAE market estimates and forecasts, 2018-2030
Figure 168 Kuwait country dynamics
Figure 169 Kuwait market estimates and forecasts, 2018-2030
Figure 170 Market share of key market players - Syndromic multiplex diagnostics market, 2023
Figure 171 Company Categorization
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Primary interviews in North America
Figure 5 Primary interviews in Europe
Figure 6 Primary interviews in APAC
Figure 7 Primary interviews in Latin America
Figure 8 Primary interviews in MEA
Figure 9 Market research approaches
Figure 10 Value-chain-based sizing & forecasting
Figure 11 QFD modeling for market share assessment
Figure 12 Market formulation & validation
Figure 13 Ophthalmic drugs market: market outlook
Figure 14 Ophthalmic drugs competitive insights
Figure 15 Parent market outlook
Figure 16 Related/ancillary market outlook
Figure 17 Penetration and growth prospect mapping
Figure 18 Industry value chain analysis
Figure 19 Ophthalmic drugs market driver impact
Figure 20 Ophthalmic drugs market restraint impact
Figure 21 Ophthalmic drugs market strategic initiatives analysis
Figure 22 Ophthalmic drugs market: Drug class movement analysis
Figure 23 Ophthalmic drugs market: Drug class outlook and key takeaways
Figure 24 Anti-Allergy market estimates and forecasts, 2018-2030
Figure 25 Anti-VEGF agents market estimates and forecasts, 2018-2030
Figure 26 Anti-inflammatory market estimates and forecasts, 2018-2030
Figure 27 Non steroidal drugs market estimates and forecasts, 2018-2030
Figure 28 Steroidal drugs market estimates and forecasts, 2018-2030
Figure 29 Anti glaucoma market estimates and forecasts, 2018-2030
Figure 30 Gene & cell therapy market estimates and forecasts, 2018-2030
Figure 31 Others market estimates and forecasts, 2018-2030
Figure 32 Ophthalmic drugs market: Disease movement analysis
Figure 33 Ophthalmic drugs market: Disease outlook and key takeaways
Figure 34 Dry eye market estimates and forecasts, 2018-2030
Figure 35 Gels market estimates and forecasts, 2018-2030
Figure 36 Eye solutions & suspensions market estimates and forecasts, 2018-2030
Figure 37 Capsules & tablets market estimates and forecasts, 2018-2030
Figure 38 Eye drops market estimates and forecasts, 2018-2030
Figure 39 Ointments market estimates and forecasts, 2018-2030
Figure 40 Allergies market estimates and forecasts, 2018-2030
Figure 41 Gels market estimates and forecasts, 2018-2030
Figure 42 Eye solutions & suspensions market estimates and forecasts, 2018-2030
Figure 43 Capsules & tablets market estimates and forecasts, 2018-2030
Figure 44 Eye drops market estimates and forecasts, 2018-2030
Figure 45 Ointments market estimates and forecasts, 2018-2030
Figure 46 Glaucoma market estimates and forecasts, 2018-2030
Figure 47 Gels market estimates and forecasts, 2018-2030
Figure 48 Eye solutions & suspensions market estimates and forecasts, 2018-2030
Figure 49 Capsules & tablets market estimates and forecasts, 2018-2030
Figure 50 Eye drops market estimates and forecasts, 2018-2030
Figure 51 Ointments market estimates and forecasts, 2018-2030
Figure 52 Infection market estimates and forecasts, 2018-2030
Figure 53 Gels market estimates and forecasts, 2018-2030
Figure 54 Eye solutions & suspensions market estimates and forecasts, 2018-2030
Figure 55 Capsules & tablets market estimates and forecasts, 2018-2030
Figure 56 Eye drops market estimates and forecasts, 2018-2030
Figure 57 Ointments market estimates and forecasts, 2018-2030
Figure 58 Retinal disorders market estimates and forecasts, 2018-2030
Figure 59 By type market estimates and forecasts, 2018-2030
Figure 60 Macular degeneration market estimates and forecasts, 2018-2030
Figure 61 Diabetic retinopathy market estimates and forecasts, 2018-2030
Figure 62 Others market estimates and forecasts, 2018-2030
Figure 63 By dosage type market estimates and forecasts, 2018-2030
Figure 64 Gels market estimates and forecasts, 2018-2030
Figure 65 Eye solutions & suspensions market estimates and forecasts, 2018-2030
Figure 66 Capsules & tablets market estimates and forecasts, 2018-2030
Figure 67 Eye drops market estimates and forecasts, 2018-2030
Figure 68 Ointments market estimates and forecasts, 2018-2030
Figure 69 Uveitis market estimates and forecasts, 2018-2030
Figure 70 Gels market estimates and forecasts, 2018-2030
Figure 71 Eye solutions & suspensions market estimates and forecasts, 2018-2030
Figure 72 Capsules & tablets market estimates and forecasts, 2018-2030
Figure 73 Eye drops market estimates and forecasts, 2018-2030
Figure 74 Ointments market estimates and forecasts, 2018-2030
Figure 75 Others market estimates and forecasts, 2018-2030
Figure 76 Gels market estimates and forecasts, 2018-2030
Figure 77 Eye solutions & suspensions market estimates and forecasts, 2018-2030
Figure 78 Capsules & tablets market estimates and forecasts, 2018-2030
Figure 79 Eye drops market estimates and forecasts, 2018-2030
Figure 80 Ointments market estimates and forecasts, 2018-2030
Figure 81 Ophthalmic drugs market: Dosage type movement analysis
Figure 82 Ophthalmic drugs market: Dosage type outlook and key takeaways
Figure 83 Gels market estimates and forecasts, 2018-2030
Figure 84 Eye solutions & suspensions market estimates and forecasts, 2018-2030
Figure 85 Capsules & tablets market estimates and forecasts, 2018-2030
Figure 86 Eye drops market estimates and forecasts, 2018-2030
Figure 87 Ointments market estimates and forecasts, 2018-2030
Figure 88 Ophthalmic drugs market: Route of administration movement analysis
Figure 89 Ophthalmic drugs market: Route of administration outlook and key takeaways
Figure 90 Topical market estimates and forecasts, 2018-2030
Figure 91 Local Ocular market estimates and forecasts, 2018-2030
Figure 92 Subconjunctival market estimates and forecasts, 2018-2030
Figure 93 Intravitreal market estimates and forecasts, 2018-2030
Figure 94 Retrobulbar market estimates and forecasts, 2018-2030
Figure 95 Intracameral market estimates and forecasts, 2018-2030
Figure 96 Sytemic market estimates and forecasts, 2018-2030
Figure 97 Ophthalmic drugs market: Product type movement analysis
Figure 98 Ophthalmic drugs market: Product type outlook and key takeaways
Figure 99 OTC market estimates and forecasts, 2018-2030
Figure 100 Prescription drugs market estimates and forecasts, 2018-2030
Figure 101 Ophthalmic drugs market: Drug type movement analysis
Figure 102 Ophthalmic drugs market: Drug type outlook and key takeaways
Figure 103 Branded drugs market estimates and forecasts, 2018-2030
Figure 104 Generic drugs market estimates and forecasts, 2018-2030
Figure 105 Global ophthalmic drugs market: Regional movement analysis
Figure 106 Global ophthalmic drugs market: Regional outlook and key takeaways
Figure 107 Global ophthalmic drugs market share and leading players
Figure 108 North America market share and leading players
Figure 109 Europe market share and leading players
Figure 110 Asia Pacific market share and leading players
Figure 111 Latin America market share and leading players
Figure 112 Middle East & Africa market share and leading players
Figure 113 North America, by country
Figure 114 North America
Figure 115 North America market estimates and forecasts, 2018-2030
Figure 116 U.S. key country dynamics
Figure 117 U.S. market estimates and forecasts, 2018-2030
Figure 118 Canada country dynamics
Figure 119 Canada market estimates and forecasts, 2018-2030
Figure 120 Mexico country dynamics
Figure 121 Mexico market estimates and forecasts, 2018-2030
Figure 122 Europe
Figure 123 Europe market estimates and forecasts, 2018-2030
Figure 124 UK country dynamics
Figure 125 UK market estimates and forecasts, 2018-2030
Figure 126 Germany
Figure 127 Germany market estimates and forecasts, 2018-2030
Figure 128 France country dynamics
Figure 129 France market estimates and forecasts, 2018-2030
Figure 130 Italy country dynamics
Figure 131 Italy market estimates and forecasts, 2018-2030
Figure 132 Spain country dynamics
Figure 133 Spain market estimates and forecasts, 2018-2030
Figure 134 Denmark country dynamics
Figure 135 Denmark market estimates and forecasts, 2018-2030
Figure 136 Sweden country dynamics
Figure 137 Sweden market estimates and forecasts, 2018-2030
Figure 138 Norway country dynamics
Figure 139 Norway market estimates and forecasts, 2018-2030
Figure 140 Asia Pacific
Figure 141 Asia Pacific market estimates and forecasts, 2018-2030
Figure 142 China country dynamics
Figure 143 China market estimates and forecasts, 2018-2030
Figure 144 Japan country dynamics
Figure 145 Japan market estimates and forecasts, 2018-2030
Figure 146 India country dynamics
Figure 147 India market estimates and forecasts, 2018-2030
Figure 148 Thailand country dynamics
Figure 149 Thailand market estimates and forecasts, 2018-2030
Figure 150 South Korea country dynamics
Figure 151 South Korea market estimates and forecasts, 2018-2030
Figure 152 Australia country dynamics
Figure 153 Australia market estimates and forecasts, 2018-2030
Figure 154 Latin America
Figure 155 Latin America market estimates and forecasts, 2018-2030
Figure 156 Brazil country dynamics
Figure 157 Brazil market estimates and forecasts, 2018-2030
Figure 158 Argentina country dynamics
Figure 159 Argentina market estimates and forecasts, 2018-2030
Figure 160 Middle East and Africa
Figure 161 Middle East and Africa market estimates and forecasts, 2018-2030
Figure 162 South Africa country dynamics
Figure 163 South Africa market estimates and forecasts, 2018-2030
Figure 164 Saudi Arabia country dynamics
Figure 165 Saudi Arabia market estimates and forecasts, 2018-2030
Figure 166 UAE country dynamics
Figure 167 UAE market estimates and forecasts, 2018-2030
Figure 168 Kuwait country dynamics
Figure 169 Kuwait market estimates and forecasts, 2018-2030
Figure 170 Market share of key market players - Syndromic multiplex diagnostics market, 2023
Figure 171 Company Categorization
Companies Mentioned
The major companies profiled in this Ophthalmic Drugs market report include:- Alcon
- Novartis AG
- Bausch Health Companies, Inc.
- Merck & Co., Inc.
- Regeneron Pharmaceuticals, Inc.
- Coherus BioSciences, Inc.
- AbbVie, Inc. (Allergan)
- Pfizer, Inc.
- Bayer AG
- Santen Pharmaceutical Co., Ltd.
- Roche (Genentech, Inc.)
- Nicox
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | February 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 38.2 Billion |
| Forecasted Market Value ( USD | $ 62.08 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
